{"transactions":[{"id":715691,"issuer":{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Tax Obligation Award","published_at":"2026-07-06T22:28:41.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":1319,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Each Tax Obligation Award is the economic equivalent of one Ordinary Share that, upon vest, will be converted to a cash payment primarily to cover tax obligations at the then-current market price of the Ordinary Shares."}],"balance_after":1319,"derivative":{"exercise_date":"2029-06-01","expiration_date":"2029-06-01","underlying":"Ordinary Shares","underlying_shares":1319},"source":{"system":"sec-edgar","filing":"0001395064-26-000275","document":"wk-form4_1783376919.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000139506426000275/wk-form4_1783376919.xml","form_type":"4"}},{"id":715690,"issuer":{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Tax Obligation Award","published_at":"2026-07-06T22:28:41.000Z","date":"2026-07-10","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1152,"price":4931.2,"value":5680742.4,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Tax Obligation Award was the economic equivalent of one Ordinary Share that, upon vest, was converted into to a cash payment primarily to cover tax obligations. Any remaining proceeds from the disposition of the associated Ordinary Shares will be delivered to the reporting person on July 10."},{"field":"date","element":"transactionDate","label":"F3","text":"Each Tax Obligation Award was the economic equivalent of one Ordinary Share that, upon vest, was converted into to a cash payment primarily to cover tax obligations. Any remaining proceeds from the disposition of the associated Ordinary Shares will be delivered to the reporting person on July 10."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 8 is a weighted average price denominated in Yen. These shares were sold in transactions at prices ranging from JPY 4,883 to JPY 5,045, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":0,"derivative":{"exercise_date":"2026-06-01","expiration_date":"2026-06-01","underlying":"Ordinary Shares","underlying_shares":1152},"source":{"system":"sec-edgar","filing":"0001395064-26-000275","document":"wk-form4_1783376919.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000139506426000275/wk-form4_1783376919.xml","form_type":"4"}},{"id":715689,"issuer":{"id":2662,"kind":"organization","name":"TAKEDA PHARMACEUTICAL CO LTD","symbol":"TAK"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-07-06T22:28:41.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":3800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents an award of restricted stock units (RSU). Each RSU represents a contingent right to receive one Ordinary Share, which will be converted into an equivalent number of American\nDepositary Shares following vest. The RSUs vest on June 1, 2029."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects the conversion of 3,100 Ordinary Shares into 6,200 American Depositary Shares upon vesting of RSUs."}],"balance_after":10400,"source":{"system":"sec-edgar","filing":"0001395064-26-000275","document":"wk-form4_1783376919.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000139506426000275/wk-form4_1783376919.xml","form_type":"4"}},{"id":726673,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-25T22:00:03.000Z","date":"2026-06-24","kind":"grant","planned":false,"acquired":true,"shares":6068,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders."}],"balance_after":6068,"derivative":{"exercise_price":99.87,"expiration_date":"2036-06-23","underlying":"Common Stock","underlying_shares":6068},"source":{"system":"sec-edgar","filing":"0001193125-26-283137","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000119312526283137/ownership.xml","form_type":"4"}},{"id":743396,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-10T21:57:24.000Z","date":"2026-06-10","kind":"grant","planned":false,"acquired":true,"shares":15200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest upon the earlier of (i) June 10, 2027 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":15200,"derivative":{"exercise_price":35.21,"expiration_date":"2036-06-10","underlying":"Common Stock","underlying_shares":15200},"source":{"system":"sec-edgar","filing":"0001193125-26-266155","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000119312526266155/ownership.xml","form_type":"4"}},{"id":748296,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-05T20:05:09.000Z","date":"2026-06-03","kind":"grant","planned":false,"acquired":true,"shares":19676,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date."}],"balance_after":19676,"derivative":{"exercise_price":29.55,"expiration_date":"2036-06-03","underlying":"Common Stock","underlying_shares":19676},"source":{"system":"sec-edgar","filing":"0001193125-26-259524","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000119312526259524/ownership.xml","form_type":"4"}},{"id":794053,"issuer":{"id":4476,"kind":"organization","name":"Hemab Therapeutics Holdings, Inc.","symbol":"COAG"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series C Preferred Stock","published_at":"2026-05-04T20:20:06.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":false,"shares":817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series B Preferred Stock and Series C Preferred Stock converted into 22 shares of common stock without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series B Preferred Stock and Series C Preferred Stock converted into 22 shares of common stock without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":17974},"source":{"system":"sec-edgar","filing":"0001193125-26-204048","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000119312526204048/ownership.xml","form_type":"4"}},{"id":794052,"issuer":{"id":4476,"kind":"organization","name":"Hemab Therapeutics Holdings, Inc.","symbol":"COAG"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B Preferred Stock","published_at":"2026-05-04T20:20:06.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":false,"shares":817,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Each share of Series B Preferred Stock and Series C Preferred Stock converted into 22 shares of common stock without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Each share of Series B Preferred Stock and Series C Preferred Stock converted into 22 shares of common stock without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":17974},"source":{"system":"sec-edgar","filing":"0001193125-26-204048","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000119312526204048/ownership.xml","form_type":"4"}},{"id":794051,"issuer":{"id":4476,"kind":"organization","name":"Hemab Therapeutics Holdings, Inc.","symbol":"COAG"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrants (Right to Buy)","published_at":"2026-05-04T20:20:06.000Z","date":"2026-01-29","kind":"grant","planned":false,"acquired":true,"shares":107338,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029."}],"balance_after":107338,"derivative":{"exercise_price":6,"expiration_date":"2036-01-28","underlying":"Common Stock","underlying_shares":107338},"source":{"system":"sec-edgar","filing":"0001193125-26-204048","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000119312526204048/ownership.xml","form_type":"4"}},{"id":794050,"issuer":{"id":4476,"kind":"organization","name":"Hemab Therapeutics Holdings, Inc.","symbol":"COAG"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:20:06.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":true,"shares":17974,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029."}],"balance_after":35948,"source":{"system":"sec-edgar","filing":"0001193125-26-204048","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000119312526204048/ownership.xml","form_type":"4"}},{"id":794049,"issuer":{"id":4476,"kind":"organization","name":"Hemab Therapeutics Holdings, Inc.","symbol":"COAG"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-04T20:20:06.000Z","date":"2026-05-04","kind":"exercise","planned":false,"acquired":true,"shares":17974,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The warrant was granted on January 29, 2026. The shares underlying the warrant vest over three years in equal monthly installments from January 1, 2026 through January 1, 2029."}],"balance_after":17974,"source":{"system":"sec-edgar","filing":"0001193125-26-204048","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000119312526204048/ownership.xml","form_type":"4"}},{"id":1101179,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-27T01:00:10.000Z","date":"2025-06-25","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 25, 2026 and (ii) the date of the next annual meeting of the Issuer's stockholders."}],"balance_after":16000,"derivative":{"exercise_price":46.47,"expiration_date":"2035-06-24","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-25-090582","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000095017025090582/ownership.xml","form_type":"4"}},{"id":1106594,"issuer":{"id":4394,"kind":"organization","name":"Rapport Therapeutics, Inc.","symbol":"RAPP"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-18T20:15:23.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":21850,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this option shall vest upon the earlier of (i) June 17, 2026 and (ii) the date of the next Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service on such vesting date."}],"balance_after":21850,"derivative":{"exercise_price":10.95,"expiration_date":"2035-06-17","underlying":"Common Stock","underlying_shares":21850},"source":{"system":"sec-edgar","filing":"0000950170-25-087902","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2012593/000095017025087902/ownership.xml","form_type":"4"}},{"id":1119996,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-06T20:05:21.000Z","date":"2025-06-04","kind":"grant","planned":false,"acquired":true,"shares":33662,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date."}],"balance_after":33662,"derivative":{"exercise_price":17.15,"expiration_date":"2035-06-04","underlying":"Common Stock","underlying_shares":33662},"source":{"system":"sec-edgar","filing":"0000950170-25-083053","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000095017025083053/ownership.xml","form_type":"4"}},{"id":1473507,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-20T21:00:08.000Z","date":"2024-06-18","kind":"grant","planned":false,"acquired":true,"shares":16000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 18, 2025 and (ii) the date of the next annual meeting of the Issuer's stockholders."}],"balance_after":16000,"derivative":{"exercise_price":31.2,"expiration_date":"2034-06-17","underlying":"Common Stock","underlying_shares":16000},"source":{"system":"sec-edgar","filing":"0000950170-24-075709","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000095017024075709/ownership.xml","form_type":"4"}},{"id":1487223,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-07T20:47:28.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":23114,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of the first anniversary of the date of grant and immediately prior to the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date."}],"balance_after":23114,"derivative":{"exercise_price":24.49,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":23114},"source":{"system":"sec-edgar","filing":"0000950170-24-070790","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000095017024070790/ownership.xml","form_type":"4"}},{"id":1839931,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director stock option (right to buy)","published_at":"2023-07-03T13:17:41.000Z","date":"2023-06-29","kind":"grant","planned":false,"acquired":true,"shares":48128,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These options were granted under the Issuer's non-employee director compensation policy."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest in full on the sooner of the one-year anniversary of the date of grant or the date of Company's next annual general shareholder meeting."}],"balance_after":48128,"derivative":{"exercise_price":10.56,"expiration_date":"2033-06-29","underlying":"Class A Ordinary Shares","underlying_shares":48128},"source":{"system":"sec-edgar","filing":"0001209191-23-040423","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000120919123040423/doc4.xml","form_type":"4"}},{"id":1850094,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-20T20:15:31.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2024 and (ii) the date of the next annual meeting of the Issuer's stockholders."}],"balance_after":12000,"derivative":{"exercise_price":27.67,"expiration_date":"2033-06-14","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0000899243-23-015965","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000089924323015965/doc4.xml","form_type":"4"}},{"id":1862767,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-08T20:47:04.000Z","date":"2023-06-06","kind":"grant","planned":false,"acquired":true,"shares":16532,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the earlier of the first anniversary of the date of grant and the date of the next year's annual meeting of stockholders, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date."}],"balance_after":16532,"derivative":{"exercise_price":34.33,"expiration_date":"2033-06-06","underlying":"Common Stock","underlying_shares":16532},"source":{"system":"sec-edgar","filing":"0000950170-23-027037","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000095017023027037/ownership.xml","form_type":"4"}},{"id":2033526,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2023-02-03T21:06:03.000Z","date":"2022-09-20","kind":"gift","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This disposition reflects a bona fide gift of 1,500 shares to charity."}],"balance_after":28528,"source":{"system":"sec-edgar","filing":"0001439222-23-000012","document":"wf-form5_167545833893976.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000143922223000012/wf-form5_167545833893976.xml","form_type":"5"}},{"id":2167894,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-09-02T20:05:38.000Z","date":"2022-09-01","kind":"grant","acquired":true,"shares":10391,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests in full on the first anniversary of the date of grant, subject to the reporting person's continued service to the board of directors of Beam Therapeutics Inc. through the vesting date."}],"balance_after":10391,"derivative":{"exercise_price":55.58,"expiration_date":"2032-09-01","underlying":"Common Stock","underlying_shares":10391},"source":{"system":"sec-edgar","filing":"0000899243-22-030271","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000089924322030271/doc4.xml","form_type":"4"}},{"id":2208164,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Units in ProKidney LP","published_at":"2022-07-14T01:29:57.000Z","date":"2022-07-11","kind":"grant","acquired":true,"shares":614013,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"These 450,156 Common Units and 163,857 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units (\"PMEL RCUs\") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through June 1, 2025. The Common Units and the PMEL RCUs do not expire."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These 450,156 Common Units and 163,857 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units (\"PMEL RCUs\") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through June 1, 2025. The Common Units and the PMEL RCUs do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"These 450,156 Common Units and 163,857 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units (\"PMEL RCUs\") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through June 1, 2025. The Common Units and the PMEL RCUs do not expire."}],"balance_after":614013,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":614013},"source":{"system":"sec-edgar","filing":"0000950103-22-012371","document":"dp177037_4-maraganore.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000095010322012371/dp177037_4-maraganore.xml","form_type":"4"}},{"id":2208163,"issuer":{"id":5181,"kind":"organization","name":"PROKIDNEY CORP."},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class B Ordinary Shares","published_at":"2022-07-14T01:29:57.000Z","date":"2022-07-11","kind":"grant","acquired":true,"shares":614013,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Class B Ordinary Share has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP (\"ProKidney\") (a \"Common Unit\"), for a Class A Ordinary Share on a one-for-one basis."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"These 450,156 Class B Ordinary Shares and 163,857 Restricted Stock Rights in respect of Class B Ordinary Shares (\"Class B PMEL RSRs\") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the \"Business Combination Agreement\") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through June 1, 2025, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These 450,156 Class B Ordinary Shares and 163,857 Restricted Stock Rights in respect of Class B Ordinary Shares (\"Class B PMEL RSRs\") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the \"Business Combination Agreement\") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through June 1, 2025, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These 450,156 Class B Ordinary Shares and 163,857 Restricted Stock Rights in respect of Class B Ordinary Shares (\"Class B PMEL RSRs\") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the \"Business Combination Agreement\") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through June 1, 2025, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire."}],"balance_after":614013,"derivative":{"underlying":"Class A Ordinary Shares","underlying_shares":614013},"source":{"system":"sec-edgar","filing":"0000950103-22-012371","document":"dp177037_4-maraganore.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000095010322012371/dp177037_4-maraganore.xml","form_type":"4"}},{"id":2223193,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2022-06-23T20:11:14.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":29307,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 21, 2022. The shares underlying this option vest as to 100% of the underlying shares on June 21, 2023."}],"balance_after":29307,"derivative":{"exercise_price":18.09,"expiration_date":"2032-06-21","underlying":"Common stock","underlying_shares":29307},"source":{"system":"sec-edgar","filing":"0001439222-22-000064","document":"wf-form4_165601503086291.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000143922222000064/wf-form4_165601503086291.xml","form_type":"4"}},{"id":2223192,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock unit","published_at":"2022-06-23T20:11:14.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":4975,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on June 21, 2022. The shares underlying the stock units will vest in full on June 21, 2023. Vested shares will be delivered to the reporting person within three business days after such shares become vested."}],"balance_after":4975,"derivative":{"underlying":"Common stock","underlying_shares":4975},"source":{"system":"sec-edgar","filing":"0001439222-22-000064","document":"wf-form4_165601503086291.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000143922222000064/wf-form4_165601503086291.xml","form_type":"4"}},{"id":2258635,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock unit","published_at":"2022-05-24T20:10:56.000Z","date":"2022-05-20","kind":"exercise","acquired":false,"shares":1585,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested"}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":1585},"source":{"system":"sec-edgar","filing":"0001439222-22-000049","document":"wf-form4_165342304013278.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000143922222000049/wf-form4_165342304013278.xml","form_type":"4"}},{"id":2258634,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2022-05-24T20:10:56.000Z","date":"2022-05-20","kind":"exercise","acquired":true,"shares":1585,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":30028,"source":{"system":"sec-edgar","filing":"0001439222-22-000049","document":"wf-form4_165342304013278.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000143922222000049/wf-form4_165342304013278.xml","form_type":"4"}},{"id":2432505,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-19T22:35:11.000Z","date":"2022-01-18","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares subject to this option shall vest in thirty-six (36) equal monthly installments over three (3) years beginning on January 18, 2022."}],"balance_after":24000,"derivative":{"exercise_price":39.61,"expiration_date":"2032-01-17","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0000899243-22-002452","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000089924322002452/doc4.xml","form_type":"4"}},{"id":2459883,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-23T22:00:40.000Z","date":"2021-12-22","kind":"tax_withholding","acquired":false,"shares":319,"price":186.02,"value":59340.38,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event."}],"balance_after":227663,"source":{"system":"sec-edgar","filing":"0001735276-21-000095","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000095/edgardoc.xml","form_type":"4"}},{"id":2459882,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-23T22:00:40.000Z","date":"2021-12-22","kind":"tax_withholding","acquired":false,"shares":2,"price":190.5,"value":381.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event."}],"balance_after":227982,"source":{"system":"sec-edgar","filing":"0001735276-21-000095","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000095/edgardoc.xml","form_type":"4"}},{"id":2459881,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-23T22:00:40.000Z","date":"2021-12-22","kind":"tax_withholding","acquired":false,"shares":6315,"price":189.13,"value":1194355.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event."}],"balance_after":227984,"source":{"system":"sec-edgar","filing":"0001735276-21-000095","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000095/edgardoc.xml","form_type":"4"}},{"id":2459880,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-23T22:00:40.000Z","date":"2021-12-21","kind":"grant","acquired":true,"shares":14167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review. One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the final performance criterion was met and the final one-third of the PSU award vested as of December 21, 2021."}],"balance_after":234299,"source":{"system":"sec-edgar","filing":"0001735276-21-000095","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000095/edgardoc.xml","form_type":"4"}},{"id":2473835,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2021-12-14T21:05:49.000Z","date":"2021-12-10","kind":"exercise","acquired":false,"shares":839,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to the remaining shares ratably at the end of each three-month period thereafter over the following thirty-three (33) months."}],"balance_after":51661,"derivative":{"exercise_price":119.13,"expiration_date":"2028-02-28","underlying":"Common Stock","underlying_shares":839},"source":{"system":"sec-edgar","filing":"0001735276-21-000091","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000091/edgardoc.xml","form_type":"4"}},{"id":2473834,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2021-12-14T21:05:49.000Z","date":"2021-12-10","kind":"exercise","acquired":false,"shares":1036,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":73964,"derivative":{"exercise_price":96.45,"expiration_date":"2024-12-17","underlying":"Common Stock","underlying_shares":1036},"source":{"system":"sec-edgar","filing":"0001735276-21-000091","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000091/edgardoc.xml","form_type":"4"}},{"id":2473833,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2021-12-14T21:05:49.000Z","date":"2021-12-10","kind":"exercise","acquired":false,"shares":1124,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":63876,"derivative":{"exercise_price":88.95,"expiration_date":"2025-12-18","underlying":"Common Stock","underlying_shares":1124},"source":{"system":"sec-edgar","filing":"0001735276-21-000091","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000091/edgardoc.xml","form_type":"4"}},{"id":2473832,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2021-12-14T21:05:49.000Z","date":"2021-12-10","kind":"exercise","acquired":false,"shares":2368,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":22632,"derivative":{"exercise_price":42.22,"expiration_date":"2026-12-20","underlying":"Common Stock","underlying_shares":2368},"source":{"system":"sec-edgar","filing":"0001735276-21-000091","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000091/edgardoc.xml","form_type":"4"}},{"id":2473831,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-14T21:05:49.000Z","date":"2021-12-10","kind":"exercise","acquired":true,"shares":2368,"price":42.22,"value":99976.96,"ownership":{"direct":true},"balance_after":220132,"source":{"system":"sec-edgar","filing":"0001735276-21-000091","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000091/edgardoc.xml","form_type":"4"}},{"id":2473830,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-14T21:05:49.000Z","date":"2021-12-10","kind":"exercise","acquired":true,"shares":839,"price":119.13,"value":99950.07,"ownership":{"direct":true},"balance_after":217764,"source":{"system":"sec-edgar","filing":"0001735276-21-000091","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000091/edgardoc.xml","form_type":"4"}},{"id":2473829,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-14T21:05:49.000Z","date":"2021-12-10","kind":"exercise","acquired":true,"shares":1124,"price":88.95,"value":99979.8,"ownership":{"direct":true},"balance_after":216925,"source":{"system":"sec-edgar","filing":"0001735276-21-000091","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000091/edgardoc.xml","form_type":"4"}},{"id":2473828,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-14T21:05:49.000Z","date":"2021-12-10","kind":"exercise","acquired":true,"shares":1036,"price":96.45,"value":99922.2,"ownership":{"direct":true},"balance_after":215801,"source":{"system":"sec-edgar","filing":"0001735276-21-000091","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000091/edgardoc.xml","form_type":"4"}},{"id":2515627,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-11-12T22:52:13.000Z","date":"2021-11-12","kind":"exercise","acquired":false,"shares":33978,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,978 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":0,"derivative":{"exercise_price":7.1,"expiration_date":"2021-11-30","underlying":"Common Stock","underlying_shares":33978},"source":{"system":"sec-edgar","filing":"0001735276-21-000089","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000089/edgardoc.xml","form_type":"4"}},{"id":2515626,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-12T22:52:13.000Z","date":"2021-11-12","kind":"sale","acquired":false,"shares":670,"price":174.34,"value":116807.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,978 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Sale prices ranged from $174.05 to $174.63."}],"balance_after":214765,"source":{"system":"sec-edgar","filing":"0001735276-21-000089","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000089/edgardoc.xml","form_type":"4"}},{"id":2515625,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-12T22:52:13.000Z","date":"2021-11-12","kind":"sale","acquired":false,"shares":683,"price":173.25,"value":118329.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,978 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Sale prices ranged from $172.90 to $173.34."}],"balance_after":215435,"source":{"system":"sec-edgar","filing":"0001735276-21-000089","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000089/edgardoc.xml","form_type":"4"}},{"id":2515624,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-12T22:52:13.000Z","date":"2021-11-12","kind":"sale","acquired":false,"shares":14518,"price":172.22,"value":2500289.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,978 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sale prices ranged from $171.86 to $172.84."}],"balance_after":216118,"source":{"system":"sec-edgar","filing":"0001735276-21-000089","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000089/edgardoc.xml","form_type":"4"}},{"id":2515623,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-12T22:52:13.000Z","date":"2021-11-12","kind":"sale","acquired":false,"shares":7742,"price":171.35,"value":1326591.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,978 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sale prices ranged from $170.85 to $171.82."}],"balance_after":230636,"source":{"system":"sec-edgar","filing":"0001735276-21-000089","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000089/edgardoc.xml","form_type":"4"}},{"id":2515622,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-12T22:52:13.000Z","date":"2021-11-12","kind":"sale","acquired":false,"shares":10365,"price":170.36,"value":1765781.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,978 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Sale prices ranged from $169.84 to $170.84."}],"balance_after":238378,"source":{"system":"sec-edgar","filing":"0001735276-21-000089","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000089/edgardoc.xml","form_type":"4"}},{"id":2515621,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-11-12T22:52:13.000Z","date":"2021-11-12","kind":"exercise","acquired":true,"shares":33978,"price":7.1,"value":241243.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,978 options exercised and sold by the reporting person were due to expire on November 30, 2021."}],"balance_after":248743,"source":{"system":"sec-edgar","filing":"0001735276-21-000089","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000089/edgardoc.xml","form_type":"4"}},{"id":2521633,"issuer":{"id":4227,"kind":"organization","name":"Beam Therapeutics Inc.","symbol":"BEAM"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-09T01:05:09.000Z","date":"2021-11-05","kind":"grant","acquired":true,"shares":13133,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to one-third of the shares subject to the option on the first anniversary of the date of grant and in equal monthly installments as to the remainder of the shares for two years thereafter, subject to the Reporting Person's continued service with the Company through each vesting date."}],"balance_after":13133,"derivative":{"exercise_price":89.53,"expiration_date":"2031-11-05","underlying":"Common Stock","underlying_shares":13133},"source":{"system":"sec-edgar","filing":"0000899243-21-043520","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000089924321043520/doc4.xml","form_type":"4"}},{"id":2602572,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-08-16T20:38:54.000Z","date":"2021-08-13","kind":"exercise","acquired":false,"shares":33979,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":33978,"derivative":{"exercise_price":7.1,"expiration_date":"2021-11-30","underlying":"Common Stock","underlying_shares":33979},"source":{"system":"sec-edgar","filing":"0001735276-21-000083","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000083/edgardoc.xml","form_type":"4"}},{"id":2602571,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-08-16T20:38:54.000Z","date":"2021-08-13","kind":"sale","acquired":false,"shares":214,"price":201.55,"value":43131.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."}],"balance_after":214765,"source":{"system":"sec-edgar","filing":"0001735276-21-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000083/edgardoc.xml","form_type":"4"}},{"id":2602570,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-08-16T20:38:54.000Z","date":"2021-08-13","kind":"sale","acquired":false,"shares":3828,"price":200.84,"value":768815.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Sale prices ranged from $200.48 to $201.43."}],"balance_after":214979,"source":{"system":"sec-edgar","filing":"0001735276-21-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000083/edgardoc.xml","form_type":"4"}},{"id":2602569,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-08-16T20:38:54.000Z","date":"2021-08-13","kind":"sale","acquired":false,"shares":23336,"price":199.92,"value":4665333.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sale prices ranged from $199.46 to $200.45."}],"balance_after":218807,"source":{"system":"sec-edgar","filing":"0001735276-21-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000083/edgardoc.xml","form_type":"4"}},{"id":2602568,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-08-16T20:38:54.000Z","date":"2021-08-13","kind":"sale","acquired":false,"shares":4160,"price":198.93,"value":827548.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sale prices ranged from $198.45 to $199.44."}],"balance_after":242143,"source":{"system":"sec-edgar","filing":"0001735276-21-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000083/edgardoc.xml","form_type":"4"}},{"id":2602567,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-08-16T20:38:54.000Z","date":"2021-08-13","kind":"sale","acquired":false,"shares":2441,"price":198.02,"value":483366.82,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Sale prices ranged from $197.44 to $198.44."}],"balance_after":246303,"source":{"system":"sec-edgar","filing":"0001735276-21-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000083/edgardoc.xml","form_type":"4"}},{"id":2602566,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-08-16T20:38:54.000Z","date":"2021-08-13","kind":"exercise","acquired":true,"shares":33979,"price":7.1,"value":241250.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."}],"balance_after":248744,"source":{"system":"sec-edgar","filing":"0001735276-21-000083","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000083/edgardoc.xml","form_type":"4"}},{"id":2687065,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock units","published_at":"2021-06-02T20:09:01.000Z","date":"2021-05-28","kind":"exercise","acquired":false,"shares":1686,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units were granted on May 28, 2020. The shares underlying the stock units will vest in full on May 28, 2021. Vested shares will be delivered to the reporting person within three businessdays after such shares become vested."}],"balance_after":0,"derivative":{"underlying":"Common stock","underlying_shares":1686},"source":{"system":"sec-edgar","filing":"0001439222-21-000054","document":"wf-form4_162266451166925.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000143922221000054/wf-form4_162266451166925.xml","form_type":"4"}},{"id":2687064,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2021-06-02T20:09:01.000Z","date":"2021-05-28","kind":"exercise","acquired":true,"shares":1686,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":28443,"source":{"system":"sec-edgar","filing":"0001439222-21-000054","document":"wf-form4_162266451166925.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000143922221000054/wf-form4_162266451166925.xml","form_type":"4"}},{"id":2687063,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common stock","published_at":"2021-06-02T20:09:01.000Z","date":"2021-02-04","kind":"gift","acquired":false,"shares":3415,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This disposition reflects a bona fide gift of 3,415 shares to charity."}],"balance_after":26757,"source":{"system":"sec-edgar","filing":"0001439222-21-000054","document":"wf-form4_162266451166925.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000143922221000054/wf-form4_162266451166925.xml","form_type":"4"}},{"id":2699248,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock options (right to buy)","published_at":"2021-05-24T20:45:46.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":8888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on May 20, 2021. The shares underlying this option vest as to 100% of the underlying shares on May 20, 2022."}],"balance_after":8888,"derivative":{"exercise_price":56.76,"expiration_date":"2031-05-20","underlying":"Common stock","underlying_shares":8888},"source":{"system":"sec-edgar","filing":"0001439222-21-000047","document":"wf-form4_162188912899512.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000143922221000047/wf-form4_162188912899512.xml","form_type":"4"}},{"id":2699247,"issuer":{"id":4499,"kind":"organization","name":"AGIOS PHARMACEUTICALS, INC."},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted stock unit","published_at":"2021-05-24T20:45:46.000Z","date":"2021-05-20","kind":"grant","acquired":true,"shares":1585,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units were granted on May 20, 2021. The shares underlying the stock units will vest in full on May 20, 2022. Vested shares will be delivered to the reporting person within three business days after such shares become vested"}],"balance_after":1585,"derivative":{"underlying":"Common stock","underlying_shares":1585},"source":{"system":"sec-edgar","filing":"0001439222-21-000047","document":"wf-form4_162188912899512.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1180432/000143922221000047/wf-form4_162188912899512.xml","form_type":"4"}},{"id":2710560,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-05-17T23:25:53.000Z","date":"2021-05-13","kind":"exercise","acquired":false,"shares":33979,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":67957,"derivative":{"exercise_price":7.1,"expiration_date":"2021-11-30","underlying":"Common Stock","underlying_shares":33979},"source":{"system":"sec-edgar","filing":"0001735276-21-000044","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000044/edgardoc.xml","form_type":"4"}},{"id":2710559,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-05-17T23:25:53.000Z","date":"2021-05-13","kind":"sale","acquired":false,"shares":1023,"price":134.37,"value":137460.51,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Sale prices ranged from $134.11 to $134.40."}],"balance_after":214765,"source":{"system":"sec-edgar","filing":"0001735276-21-000044","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000044/edgardoc.xml","form_type":"4"}},{"id":2710558,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-05-17T23:25:53.000Z","date":"2021-05-13","kind":"sale","acquired":false,"shares":1624,"price":133.56,"value":216901.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Sale prices ranged from $132.97 to $133.77."}],"balance_after":215788,"source":{"system":"sec-edgar","filing":"0001735276-21-000044","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000044/edgardoc.xml","form_type":"4"}},{"id":2710557,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-05-17T23:25:53.000Z","date":"2021-05-13","kind":"sale","acquired":false,"shares":3481,"price":132.32,"value":460605.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Sale prices ranged from $131.84 to $132.78."}],"balance_after":217412,"source":{"system":"sec-edgar","filing":"0001735276-21-000044","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000044/edgardoc.xml","form_type":"4"}},{"id":2710556,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-05-17T23:25:53.000Z","date":"2021-05-13","kind":"sale","acquired":false,"shares":11203,"price":131.18,"value":1469609.54,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Sale prices ranged from $130.82 to $131.81."}],"balance_after":220893,"source":{"system":"sec-edgar","filing":"0001735276-21-000044","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000044/edgardoc.xml","form_type":"4"}},{"id":2710555,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-05-17T23:25:53.000Z","date":"2021-05-13","kind":"sale","acquired":false,"shares":9121,"price":130.34,"value":1188831.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sale prices ranged from $129.81 to $130.81."}],"balance_after":232096,"source":{"system":"sec-edgar","filing":"0001735276-21-000044","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000044/edgardoc.xml","form_type":"4"}},{"id":2710554,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-05-17T23:25:53.000Z","date":"2021-05-13","kind":"sale","acquired":false,"shares":4512,"price":129.32,"value":583491.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sale prices ranged from $128.80 to $129.77."}],"balance_after":241217,"source":{"system":"sec-edgar","filing":"0001735276-21-000044","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000044/edgardoc.xml","form_type":"4"}},{"id":2710553,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-05-17T23:25:53.000Z","date":"2021-05-13","kind":"sale","acquired":false,"shares":3015,"price":128.3,"value":386824.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Sale prices ranged from $127.73 to $128.73."}],"balance_after":245729,"source":{"system":"sec-edgar","filing":"0001735276-21-000044","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000044/edgardoc.xml","form_type":"4"}},{"id":2710552,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-05-17T23:25:53.000Z","date":"2021-05-13","kind":"exercise","acquired":true,"shares":33979,"price":7.1,"value":241250.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."}],"balance_after":248744,"source":{"system":"sec-edgar","filing":"0001735276-21-000044","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000044/edgardoc.xml","form_type":"4"}},{"id":2743240,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-04-21T22:20:57.000Z","date":"2021-04-20","kind":"tax_withholding","acquired":false,"shares":270,"price":134.6196,"value":36347.292,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event."}],"balance_after":214765,"source":{"system":"sec-edgar","filing":"0001735276-21-000037","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000037/edgardoc.xml","form_type":"4"}},{"id":2743239,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-04-21T22:20:57.000Z","date":"2021-04-20","kind":"tax_withholding","acquired":false,"shares":7237,"price":131.75,"value":953474.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event."}],"balance_after":215035,"source":{"system":"sec-edgar","filing":"0001735276-21-000037","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000037/edgardoc.xml","form_type":"4"}},{"id":2743238,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-04-21T22:20:57.000Z","date":"2021-04-19","kind":"grant","acquired":true,"shares":16236,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 26, 2020, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2019 year-end compensation review.  One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the first performance criterion was met and one-third of the PSU award vested as of April 19, 2021."}],"balance_after":222272,"source":{"system":"sec-edgar","filing":"0001735276-21-000037","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000037/edgardoc.xml","form_type":"4"}},{"id":2830067,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-26T21:03:20.000Z","date":"2021-02-25","kind":"exercise","acquired":false,"shares":33979,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F16","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":101936,"derivative":{"exercise_price":7.1,"expiration_date":"2021-11-30","underlying":"Common Stock","underlying_shares":33979},"source":{"system":"sec-edgar","filing":"0001735276-21-000020","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000020/edgardoc.xml","form_type":"4"}},{"id":2830066,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option  (right to buy)","published_at":"2021-02-26T21:03:20.000Z","date":"2021-02-24","kind":"grant","acquired":true,"shares":79998,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F14","text":"Represents the time-vested stock option portion of the reporting person's Annual Equity Award for 2020. The reporting person also received 42,879 performance stock units that will vest upon the achievement of four specific performance conditions, which will be reported on a Form 4 if and when each performance condition is met and the performance stock units vest."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F15","text":"The stock option vests as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional 6.25% of the shares each successive three month period thereafter."}],"balance_after":79998,"derivative":{"exercise_price":151.59,"expiration_date":"2031-02-23","underlying":"Common Stock","underlying_shares":79998},"source":{"system":"sec-edgar","filing":"0001735276-21-000020","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000020/edgardoc.xml","form_type":"4"}},{"id":2830065,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-26T21:03:20.000Z","date":"2021-02-25","kind":"sale","acquired":false,"shares":599,"price":154.59,"value":92599.41,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"Sale prices ranged from $154.37 to $154.68."}],"balance_after":206036,"source":{"system":"sec-edgar","filing":"0001735276-21-000020","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000020/edgardoc.xml","form_type":"4"}},{"id":2830064,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-26T21:03:20.000Z","date":"2021-02-25","kind":"sale","acquired":false,"shares":431,"price":153.33,"value":66085.23,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Sale prices ranged from $153.05 to $153.90."}],"balance_after":206635,"source":{"system":"sec-edgar","filing":"0001735276-21-000020","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000020/edgardoc.xml","form_type":"4"}},{"id":2830063,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-26T21:03:20.000Z","date":"2021-02-25","kind":"sale","acquired":false,"shares":1138,"price":152.46,"value":173499.48,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"Sale prices ranged from $151.92 to $152.76."}],"balance_after":207066,"source":{"system":"sec-edgar","filing":"0001735276-21-000020","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000020/edgardoc.xml","form_type":"4"}},{"id":2830062,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-26T21:03:20.000Z","date":"2021-02-25","kind":"sale","acquired":false,"shares":1415,"price":151.31,"value":214103.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"Sale prices ranged from $150.88 to $151.68."}],"balance_after":208204,"source":{"system":"sec-edgar","filing":"0001735276-21-000020","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000020/edgardoc.xml","form_type":"4"}},{"id":2830061,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-26T21:03:20.000Z","date":"2021-02-25","kind":"sale","acquired":false,"shares":2054,"price":150.22,"value":308551.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"Sale prices ranged from $149.73 to $150.62."}],"balance_after":209619,"source":{"system":"sec-edgar","filing":"0001735276-21-000020","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000020/edgardoc.xml","form_type":"4"}},{"id":2830060,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-26T21:03:20.000Z","date":"2021-02-25","kind":"sale","acquired":false,"shares":1364,"price":148.96,"value":203181.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Sale prices ranged from $148.66 to $149.65."}],"balance_after":211673,"source":{"system":"sec-edgar","filing":"0001735276-21-000020","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000020/edgardoc.xml","form_type":"4"}},{"id":2830059,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-26T21:03:20.000Z","date":"2021-02-25","kind":"sale","acquired":false,"shares":4375,"price":148,"value":647500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Sale prices ranged from $147.60 to $148.59."}],"balance_after":213037,"source":{"system":"sec-edgar","filing":"0001735276-21-000020","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000020/edgardoc.xml","form_type":"4"}},{"id":2830058,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-26T21:03:20.000Z","date":"2021-02-25","kind":"sale","acquired":false,"shares":6097,"price":146.98,"value":896137.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Sale prices ranged from $146.59 to $147.59."}],"balance_after":217412,"source":{"system":"sec-edgar","filing":"0001735276-21-000020","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000020/edgardoc.xml","form_type":"4"}},{"id":2830057,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-26T21:03:20.000Z","date":"2021-02-25","kind":"sale","acquired":false,"shares":9376,"price":146.13,"value":1370114.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sale prices ranged from $145.55 to $146.55."}],"balance_after":223509,"source":{"system":"sec-edgar","filing":"0001735276-21-000020","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000020/edgardoc.xml","form_type":"4"}},{"id":2830056,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-26T21:03:20.000Z","date":"2021-02-25","kind":"sale","acquired":false,"shares":6129,"price":145.15,"value":889624.35,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sale prices ranged from $144.54 to $145.54."}],"balance_after":232885,"source":{"system":"sec-edgar","filing":"0001735276-21-000020","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000020/edgardoc.xml","form_type":"4"}},{"id":2830055,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-26T21:03:20.000Z","date":"2021-02-25","kind":"sale","acquired":false,"shares":1001,"price":143.88,"value":144023.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Sale prices ranged from $143.50 to $144.43."}],"balance_after":239014,"source":{"system":"sec-edgar","filing":"0001735276-21-000020","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000020/edgardoc.xml","form_type":"4"}},{"id":2830054,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-26T21:03:20.000Z","date":"2021-02-25","kind":"exercise","acquired":true,"shares":33979,"price":7.1,"value":241250.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 9, 2020. The 33,979 options exercised and sold by the reporting person were due to expire on November 30, 2021."}],"balance_after":240015,"source":{"system":"sec-edgar","filing":"0001735276-21-000020","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000020/edgardoc.xml","form_type":"4"}},{"id":2859702,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Performance Stock Option 2017 (right to buy)","published_at":"2021-02-16T21:08:49.000Z","date":"2021-02-11","kind":"grant","acquired":true,"shares":17504,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On March 1, 2018, the reporting person was granted a performance based stock option to purchase shares of ALNY common stock in connection with the 2017 year-end compensation review. One third of the shares subject to the option vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the third performance criterion was met and the option vested as to the final one third of the shares as of February 11, 2021."}],"balance_after":52500,"derivative":{"exercise_price":119.13,"exercise_date":"2021-02-11","expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":17504},"source":{"system":"sec-edgar","filing":"0001735276-21-000013","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000013/edgardoc.xml","form_type":"4"}},{"id":2859701,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-16T21:08:49.000Z","date":"2021-02-12","kind":"tax_withholding","acquired":false,"shares":307,"price":151.937,"value":46644.659,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event."}],"balance_after":206036,"source":{"system":"sec-edgar","filing":"0001735276-21-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000013/edgardoc.xml","form_type":"4"}},{"id":2859700,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-16T21:08:49.000Z","date":"2021-02-12","kind":"tax_withholding","acquired":false,"shares":5412,"price":156,"value":844272.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the PSU award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting event."}],"balance_after":206343,"source":{"system":"sec-edgar","filing":"0001735276-21-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000013/edgardoc.xml","form_type":"4"}},{"id":2859699,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-02-16T21:08:49.000Z","date":"2021-02-11","kind":"grant","acquired":true,"shares":14166,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On February 28, 2019, the reporting person was granted performance-based restricted stock units (PSU) in connection with the 2018 year-end compensation review.  One third of the PSU award vests upon the achievement of each of three specific clinical development, regulatory or commercial events. The People, Culture and Compensation Committee of the Board determined that the second performance criterion was met and an additional one-third of the PSU award vested as of February 11, 2021."}],"balance_after":211755,"source":{"system":"sec-edgar","filing":"0001735276-21-000013","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527621000013/edgardoc.xml","form_type":"4"}},{"id":2971510,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-11-20T21:02:37.000Z","date":"2020-11-19","kind":"exercise","acquired":false,"shares":34765,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":0,"derivative":{"exercise_price":9.14,"expiration_date":"2020-12-08","underlying":"Common Stock","underlying_shares":34765},"source":{"system":"sec-edgar","filing":"0001735276-20-000103","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000103/edgardoc.xml","form_type":"4"}},{"id":2971509,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-11-20T21:02:37.000Z","date":"2020-11-19","kind":"sale","acquired":false,"shares":102,"price":126.62,"value":12915.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020."}],"balance_after":197589,"source":{"system":"sec-edgar","filing":"0001735276-20-000103","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000103/edgardoc.xml","form_type":"4"}},{"id":2971508,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-11-20T21:02:37.000Z","date":"2020-11-19","kind":"sale","acquired":false,"shares":10187,"price":125.35,"value":1276940.45,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sale prices ranged from $125.03 to $125.89."}],"balance_after":197691,"source":{"system":"sec-edgar","filing":"0001735276-20-000103","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000103/edgardoc.xml","form_type":"4"}},{"id":2971507,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-11-20T21:02:37.000Z","date":"2020-11-19","kind":"sale","acquired":false,"shares":5489,"price":124.49,"value":683325.61,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sale prices ranged from $124.02 to $125.02."}],"balance_after":207878,"source":{"system":"sec-edgar","filing":"0001735276-20-000103","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000103/edgardoc.xml","form_type":"4"}},{"id":2971506,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-11-20T21:02:37.000Z","date":"2020-11-19","kind":"sale","acquired":false,"shares":18987,"price":123.55,"value":2345843.85,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Sale prices ranged from $123.01 to $124.01."}],"balance_after":213367,"source":{"system":"sec-edgar","filing":"0001735276-20-000103","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000103/edgardoc.xml","form_type":"4"}},{"id":2971505,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-11-20T21:02:37.000Z","date":"2020-11-19","kind":"exercise","acquired":true,"shares":34765,"price":9.14,"value":317752.1,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020."}],"balance_after":232354,"source":{"system":"sec-edgar","filing":"0001735276-20-000103","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000103/edgardoc.xml","form_type":"4"}},{"id":3050082,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (right to buy)","published_at":"2020-08-21T20:06:57.000Z","date":"2020-08-20","kind":"exercise","acquired":false,"shares":34765,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vested as to 25% of the shares on the 1st anniversary of the date of the stock option grant and as to an additional  6.25% of the shares each successive three month period thereafter."}],"balance_after":34765,"derivative":{"exercise_price":9.14,"expiration_date":"2020-12-08","underlying":"Common Stock","underlying_shares":34765},"source":{"system":"sec-edgar","filing":"0001735276-20-000095","document":"edgardoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000095/edgardoc.xml","form_type":"4"}},{"id":3050081,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-08-21T20:06:57.000Z","date":"2020-08-20","kind":"sale","acquired":false,"shares":8542,"price":136.86,"value":1169058.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Sale prices ranged from $136.59 to $137.55."}],"balance_after":197589,"source":{"system":"sec-edgar","filing":"0001735276-20-000095","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000095/edgardoc.xml","form_type":"4"}},{"id":3050080,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-08-21T20:06:57.000Z","date":"2020-08-20","kind":"sale","acquired":false,"shares":21448,"price":136.07,"value":2918429.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Sale prices ranged from $135.58 to $136.58."}],"balance_after":206131,"source":{"system":"sec-edgar","filing":"0001735276-20-000095","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000095/edgardoc.xml","form_type":"4"}},{"id":3050079,"issuer":{"id":3132,"kind":"organization","name":"ALNYLAM PHARMACEUTICALS, INC.","symbol":"ALNY"},"owners":[{"id":32216,"kind":"person","name":"MARAGANORE JOHN","position":1,"cik":"0001180432","reported_name":"MARAGANORE JOHN","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2020-08-21T20:06:57.000Z","date":"2020-08-20","kind":"sale","acquired":false,"shares":4775,"price":135.09,"value":645054.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2019. The 34,765 options exercised and sold by the reporting person were due to expire on December 8, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Sale prices ranged from $134.52 to $135.52."}],"balance_after":227579,"source":{"system":"sec-edgar","filing":"0001735276-20-000095","document":"edgardoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1178670/000173527620000095/edgardoc.xml","form_type":"4"}}],"next_cursor":"2020-08-21T20:06:57.000000Z,3050079"}